Using the TiLV virus genome sequence to develop a recombinant oral vaccine in microalgae. Comment to the article "Complete Genome Sequence of a Tilapia Lake Virus Isolate Obtained from Nile Tilapia (Oreochromis niloticus)"
Fiche du document
1 janvier 2020
- handle: 10670/1.7wtlt0
Ce document est lié à :
10.21640/ns.v12i24.2073
info:eu-repo/semantics/openAccess
Mots-clés
microalgae TiLV vaccine viral vectorSujets proches
Tilapia nilotica Oreochromis niloticusCiter ce document
Bernardo Bañuelos-Hernández et al., « Using the TiLV virus genome sequence to develop a recombinant oral vaccine in microalgae. Comment to the article "Complete Genome Sequence of a Tilapia Lake Virus Isolate Obtained from Nile Tilapia (Oreochromis niloticus)" », Nova Scientia, ID : 10670/1.7wtlt0
Métriques
Partage / Export
Résumé
High mortality and dissemination rates of the emerging virus TiLV (Tilapia lake Virus) leads the researcher to develop a novel strategies to prevent these kind of infections in the fish. In viral diseases, vaccination is the most recommended method for prevention. In this context and considering the genome sequences of TiLV virus published in the article “Complete Genome Sequence of a Tilapia Lake Virus Isolate Obtained from Nile Tilapia (Oreochromis niloticus)”, we propose to produce a recombinant oral vaccine through microalgae biotechnology using viral vectors.